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A B S T R A C T
Mouse hindlimb ischemia has been widely used as a model to study peripheral artery disease. Genetic
modulation of the enzymatic source of oxidants or components of the antioxidant system reveal that
physiological levels of oxidants are essential to promote the process of arteriogenesis and angiogenesis after
femoral artery occlusion, although mice with diabetes or atherosclerosis may have higher deleterious levels of
oxidants. Therefore, ﬁne control of oxidants is required to stimulate vascularization in the limb muscle. Oxidants
transduce cellular signaling through oxidative modiﬁcations of redox sensitive cysteine thiols. Of particular
importance, the reversible modiﬁcation with abundant glutathione, called S-glutathionylation (or GSH adducts),
is relatively stable and alters protein function including signaling, transcription, and cytoskeletal arrangement.
Glutaredoxin-1 (Glrx) is an enzyme which catalyzes reversal of GSH adducts, and does not scavenge oxidants
itself. Glrx may control redox signaling under ﬂuctuation of oxidants levels. In ischemic muscle increased GSH
adducts through Glrx deletion improves in vivo limb revascularization, indicating endogenous Glrx has anti-
angiogenic roles. In accordance, Glrx overexpression attenuates VEGF signaling in vitro and ischemic
vascularization in vivo. There are several Glrx targets including HIF-1α which may contribute to inhibition of
vascularization by reducing GSH adducts. These animal studies provide a caution that excess antioxidants may
be counter-productive for treatment of ischemic limbs, and highlights Glrx as a potential therapeutic target to
improve ischemic limb vascularization.
1. Introduction
Use of antioxidants has gained prevalence to protect and improve
our health, based on the assertion that excess oxidants are harmful
introducing cellular “oxidative stress”. However, clinical studies have
failed to prove the eﬃcacy of antioxidant therapy to combat cardio-
vascular disease [1,2]. In contrast, growing evidence supports the
concept that physiological levels of oxidants or free radicals are
essential to cellular signaling and to promote ischemic angiogenesis
[3]. Vascular endothelial growth factor (VEGF)-induced reactive oxy-
gen species (ROS) is an important component for mitotic signaling [4].
The in vivo roles of oxidants and antioxidants have been investigated
using genetically modiﬁed mice which overexpress or lack speciﬁc
enzymes involved in controlling redox homeostasis. For example,
decrease in oxidants by Nox2 deletion impaired revascularization in
ischemic limb study [5,6], while upregulated Nox4 expression im-
proved revascularization in ischemic limbs [7,8], indicating beneﬁcial
eﬀects of elevated oxidants. This paradoxical concept is possibly true
also in aging. Although oxidative stress has been considered to be a
promoting factor for aging process [9], recent studies show that modest
elevation of oxidants increases lifespan at least in C. elegans. [10].
In this review we use the term “Oxidants” as a general term
including reactive oxygen species (ROS, e.g. superoxide anion) and
reactive nitrogen species (RNS, e.g. peroxynitrite). Oxidants control
cellular activities including proliferation, migration, apoptosis, and
transcription through post-translational modiﬁcations of various target
proteins. The role of NADPH oxidases (NOX) as a source of oxidants in
VEGF signaling and angiogenesis has been well studied and reviewed
elsewhere [11,12]. Recently a reversible modiﬁcation on protein thiols
is emerging as a mechanism which generates “redox signaling” [13,14].
This review will highlight how in vivo animal studies are shedding light
on the role of oxidants and redox signaling in ischemic vascularization,
focusing on hindlimb ischemia model. Emphasize will be placed on the
importance of oxidative modiﬁcation with protein glutathione (GSH)
adducts, or S-glutathionylation, on vascularization.
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2. Animal models of ischemic neovascularization
In vitro assays assessing endothelial or macrophage angiogenic
function do not always reﬂect the in vivo outcome [15]. Cell-cell
interaction, paracrine factors, and tissue speciﬁc components make
complex microenvironment to support in vivo vessel formation. After
tissue is exposed to ischemia, impaired blood ﬂow is recovered by
capillary formation (angiogenesis) and artery formation (arteriogen-
esis). Angiogenesis is deﬁned as the new capillary formation form pre-
existing vessels, while arteriogenesis refers to remodeling of larger
vessels (arterioles and arteries) which may be formed from pre-existing
collateral vessels or anastomosis [16] and also can be developed from
new capillaries. Revascularization after artery occlusion is considered
as the combined process of arteriogenesis and angiogenesis, and the
regulatory mechanisms are still not fully understood [17,18]. Herein we
mainly focus on the hindlimb ischemia model, and additionally
compare with cardiac ischemia by coronary artery occlusion.
2.1. Role of oxidants in hindlimb ischemia models
Blood ﬂow recovery after unilateral femoral artery ligation in
rodents is usually assessed by LASER Doppler imaging [19] as shown
in Fig. 1. Capillary density of ischemic muscles, motor function,
necrotic area, and micro-computed tomographic imaging or angiogra-
phy are used to support the ﬁnding [18]. Although factors such as
animal strain, surgical procedure, and age inﬂuence the outcome, the
method is a gold standard to study regulatory mechanism of arteriogen-
esis and angiogenesis following ischemia. The roles of oxidants and
antioxidants in ischemic limb revascularization are examined using
genetically modiﬁed mice, and the major studies are summarized in
Table 1.
In an early study elucidated the important role of eNOS-derived
nitric oxide (NO). Dietary supplement of L-arginine promoted eNOS
activity and improved vascularity in rabbit ischemic limbs. In accor-
dance with that, eNOS-/- mice showed impaired neovascularization.
Yet, the expression of vascular endothelial growth factor (VEGF) was
unaltered. The impaired vascularization was not improved by admin-
istration of VEGF in eNOS-/- mice [20]. Taken together this suggests
that eNOS is downstream of VEGF and likely eNOS-derived NO or RNS
is required for VEGF signaling.
NADPH oxidases (NOX) are a major source of oxidants in the
vasculature. The NOX family of enzymes has diﬀerential cell type
expression and subcellular localization; in addition, they produce
diﬀerent oxidants. Deletion of NOX2 showed impaired ischemic
vascularization [5,6]. Whereas, when NOX4, an enzyme which speci-
ﬁcally produces hydrogen peroxide (H2O2), is overexpressed in en-
dothelial cells, ischemic vascularization is improved [7,8] which is in
accordance with NOX4 improving endothelial function [21]. In con-
trast, when NOX4 is deleted, ischemic revascularization was impaired
[8,22]. In addition, the protective role of oxidants in particular H2O2 is
supported by endothelial-speciﬁc overexpression of catalase which
shows impaired vascularization in mouse ischemic limb [23]. Catalase
overexpression in myeloid linage cells also showed impaired vascular-
ization associated with decreased macrophages inﬁltration and inﬂam-
matory responses [24]. Deletion of the antioxidant enzyme extracel-
lular superoxide dismutase (ecSOD) causes impaired ischemic vascular-
ization, but the protective role of ecSOD in vascularization may not be
due to the lower level of superoxide anion, but rather lack of conversion
of superoxide anion to H2O2 which is essential to promote VEGF
signaling [25,26].
2.2. Role of antioxidants in hindlimb ischemia models
These studies indicate that physiological level of oxidants are
required to promote ischemic vascularization. Anti-angiogenic role of
endogenous antioxidants is shown in mice which are deﬁcient of
nuclear factor erythroid 2-related factor 2 (Nrf 2). Nrf2 is a transcrip-
tion factor which interacts with antioxidant response element and
promotes transcription of genes for antioxidants or detoxifying en-
zymes. Nrf2-/- mice improved vascularization after hindlimb ischemia
in association with decreased hemeoxygenase-1, thioredoxin (Trx)-1,
and total GSH level and increase in inﬂammatory responses [27]. Of
interest, another paper [15] showed that in vitro angiogenic responses
were Nrf2-dependent in endothelial cells and myeloid cells, but Nrf2-/-
Fig. 1. Hindlimb Ischemia model by femoral artery ligation. After femoral artery ligation, blood ﬂow recovery is assessed by LASER Doppler imaging. An example of images and blood
ﬂow ratio (left/right foot) during 2 weeks post-surgery is shown from glutaredoxin (Glrx) transgenic mice study (see Ref. [48]). The upper cartoon indicates that some of oxidants related
genes inﬂuence ischemic neovascularization. NOXs (NADPH oxidases), eNOS (endothelial nitric oxide synthase), Trx (thioredoxin) are promoting, while catalase, Glrx and Nrf2 are
inhibiting ischemic neovascularization. Details are described in the text and references are listed in Table 1.
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mice had improved in vivo ischemic vascularization consistent with the
former study. This was in association with decreased antioxidant
capacity and increased inﬂammatory responses.
GSH is the most abundant low molecular weight thiol in the cell,
consist of glutamate, cysteine, and glycine, and controls cellar redox
status by scavenging radicals. Endogenous GSH is produced by ATP-
dependent reactions catalyzed by glutamate-cysteine ligase (GCL) and
GSH synthase [28]. GSH synthase is transcriptionally regulated by Nrf2,
and GCL consists of catalytic (GCLC) and modiﬁer (GCLM) subunits.
While deletion of Gclc in mice is lethal, Gclm-/- mice are viable and look
normal with decreased GSH in tissues. Gclm-/- mice demonstrated
exacerbated cardiac function after ischemia-reperfusion [29] or pres-
sure-overload [30] compared to wild type mice. In hindlimb ischemia
studies, Gclm-/- mice did not show diﬀerent neovascularization from
wild type mice. Instead Gclm+/- heterozygous mice showed better
blood ﬂow recovery and endothelial cell density [31]. The authors
measured superoxide anion levels in ischemic muscles and suggested
mild increase in superoxide in Gclm+/- mice stimulated VEGF produc-
tion and vascularization, but higher superoxide levels in Gclm-/- mice
did not. Interestingly, the diﬀerences in superoxide levels were at
picomolar level. Although total glutathione was decreased, the GSH/
GSSG ratio was increased in the ischemic muscle of Gclm+/- mice and
decreased of the muscle of Gclm-/- mice [31]. Increases in GSH
reductase activity may explain the higher GSH/GSSG ratio [29].
2.3. Hindlimb ischemia in pathological models
Thus, the levels of oxidants are critical to control cellular signaling.
Low levels of oxidants in physiological conditions are necessary to
promote angiogenesis, but high levels of oxidants in pathological
conditions such as diabetes can be harmful. In fact, impaired ische-
mia-induced vascularization was improved by NOX2-/- mice after
smoke exposure [32], high-cholesterol diet [33], or streptozotocin
(STZ)-induced diabetes [34]. These data are contrast to the report
showing angiogenic role of NOX2 in ischemic limb revascularization
[5], and indicate that oxidants derived from NOX2 can inhibit
angiogenesis under oxidative stress. Inhibiting NOX2 likely activates
endothelial progenitor cells [33,34] and increases VEGF-A levels in
diabetic ischemic muscle [34], suggesting production of VEGF-A may
be aﬀected in association with oxidative stress. Mitochondria-targeted
catalase overexpression was also protective in high-fat fed mice, and
decreased necrotic area and improved myopathy and mitochondrial
dysfunction despite no signiﬁcant improvement of limb blood ﬂow
recovery. Unlike high-fat fed mice, mitochondrial catalase overexpres-
sion did not improve ischemic limb recovery in chow-fed mice [35].
This study indicates that excess mitochondrial oxidants in diet-induced
diabetes may be relating to impaired muscle degeneration after
ischemia, but its relation to neovascularization is obscure. Increase
nitric oxide bioavailability by phosphodiesterase inhibitor can improve
ischemic limb vascularization in hypercholesterolemic apolipoprotein
E-/- mice [36]. However, excess antioxidants therapy may not be
eﬀective as shown in clinical trials because it may aﬀect physiological
function of oxidants. Impaired blood ﬂow recovery in atherosclerotic
animals was improved by exogenous VEGF [37,38], indicating that
VEGF signaling is still functional and augmenting VEGF production is
important in the atherosclerotic condition.
2.4. The role of thiol modifying enzymes in hindlimb ischemia
Thioredoxin (Trx) and glutaredoxin (Glrx) are enzymes which
reduce protein thiols as part of the cellular antioxidant systems. Trx
dominantly reduces intra- or inter- protein disulﬁde (-S-S-) and Glrx
more speciﬁcally reduces protein-GSH adducts (R-S-SG). Glrx was
originally discovered in Escherichia coli lacking Trx [39]. However,
Glrx is not just a compensatory enzyme for Trx, but has distinct roles
[40]. Overexpression of mitochondrial Trx 2 in endothelial cells
promoted vascularization after hindlimb ischemia by increasing NO
bioavailability and inhibiting apoptosis signaling kinase-1 (ASK-1)
activity [41]. Cytosolic isoform Trx 1 is also protective, promoting
endothelial angiogenic activities, and interacting with ASK-1 to inhibit
pro-apoptotic pathways [42]. Trx 1 overexpression is protective in
mouse myocardial infarction [43] and ex vivo ischemia-reperfusion
[44]. Thioredoxin-interacting protein (TXNIP) has been considered as
an endogenous Trx inhibitor which is increased in diabetes. Interest-
ingly, knockdown TXNIP improved ischemic vascularization in STZ-
induced diabetic mice. However, the experiment using a mutant of Trx
binding site suggested this anti-angiogenic eﬀects of TXNIP may be
independent of Trx activity [45].
There are two isoforms of Glrx in mammalian cells. Glrx1 is
localized mainly in the cytoplasm which we refer as Glrx, and Glrx2
is localized in mitochondria or the nucleus depending on splice
variants. Human Glrx2 exhibits only 34–36% identity with Glrx1 and
its speciﬁc activity is less than 10% of Glrx1 [46]. In contrast to Trx
which is angiogenic, Glrx inhibits endothelial cell angiogenic properties
Table 1
The role of oxidants related enzymes/genes in mouse models of ischemic vascularization.
Gene Mouse Disease
model
Outcome/
vascularization
Comments Ref.
NOX2 KO HLI Impaired [5,6]
KO HLI after
smoke
exposure
Protective [32]
KO HLI after
HFD
Protective [33]
KO HLI after
STZ-
diabetes
Protective [34]
KO MI Protective Cardiac
function
[53]
EC-TG MI No eﬀects [55]
CM-TG MI Exacerbated Hypertrophy,
ﬁbrosis
[55]
NOX4 EC-TG HLI Protective [7]
EC-TG HLI Protective [8]
EC-DN HLI Impaired [8]
KO HLI Impaired [22]
eNOS KO HLI Impaired [20]
Catalase EC-TG HLI Impaired [23]
Mito-TG HLI after
HFD
Protective Myopathy less
vascularity: NS
[35]
MCL-TG HLI Impaired [24]
MCL-TG MI Protective Infarct size
smaller
[57]
ecSOD KO HLI Impaired [25,26]
Trx1 TG MI Protective Cardiac
function
[43]
Trx2 EC-TG HLI Protective [41]
Glrx TG MI Protective Cardiac
function
[58]
TG HLI Impaired [48]
KO HLI Protective [49]
GCLM KO MI (I/R) Impaired function Decreased GSH [29]
Hetero HLI Protective KO (-/-) no
eﬀect
[31]
Nrf2 KO HLI Protective Trx decreased [27]
KO HLI Protective Cytokines
increased
[15]
Hindlimb and cardiac ischemia studies using genetically modiﬁed mice of redox-related
genes. NOX: NADPH oxidase, eNOS: endothelial nitric oxide synthase, ecSOD: extra-
cellular superoxide dismutase, Trx: thioredoxin, Glrx: glutaredoxin-1, GCLM: glutamate-
cysteine ligase modiﬁer, Nrf2: nuclear factor erythroid 2-related factor 2. KO: global
knockout (-/-), Hetero: heterozygous (+/-) mice, TG: global transgenic overexpression,
EC-TG: endothelial-speciﬁc overexpression, CM-TG: cardiomyocyte-speciﬁc overexpres-
sion, EC-DN: endothelial-speciﬁc dominant negative, Mito-TG: targeted expression to
mitochondria, MCL-TG: Myeloid cell linage-speciﬁc overexpression, HLI: hindlimb
ischemia model, MI: myocardial infarction model, I/R: ischemia-reperfusion, HFD: high
fat diet.
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[47,48]. Glrx overexpressing transgenic (TG) mice impaired [48] and
Glrx-/- mice improved ischemic limb vascularization [49]. Glrx controls
protein-GSH adducts in the presence of GSH, glutathione reductase, and
NADPH, but does not function as an antioxidant per se [50]. Glrx-/- mice
rather indicated lower oxidants generation after angiotensin II infusion
[51]. The role of Glrx on redox signaling and ischemic vascularization
will be further discussed later part of this review [52].
2.5. The role of oxidants in cardiac ischemia vs limb ischemia
Cardiac ischemia is studied in animals by ligation of the left anterior
descending artery or alternatively transient occlusion followed by
reperfusion. The outcome is evaluated by vascularity, apoptosis, infarct
area, but mainly assessed by recovery of cardiac function. Inhibiting
oxidants seems to be more protective for cardiac ischemia. Global
NOX2 deletion is protective in cardiac function with less apoptosis and
interstitial ﬁbrosis although cardiac infarct size was similar between
NOX2-/- and WT mice [53]. Mice lacking p47phox, cytosolic NOX
components, showed similar outcome [54]. This is a clear contrast to
the impaired ischemic limb vascularization observed in NOX2 deﬁcient
mice [5,6]. Endothelial speciﬁc NOX2 overexpression has no eﬀect on
cardiac function in myocardial infarction model [55] even though
oxidants derived from endothelial NOX2 contribute to cardiac diastolic
dysfunction after angiotensin II infusion [56]. In contrast, mice with
NOX2 overexpression restricted in cardiomyocytes have enhanced
cardiac hypertrophy and ﬁbrosis post myocardial infarction [55]. As
mentioned previously, Gclm-/- mice decreased GSH levels and exacer-
bated cardiac infarction and dysfunction after ischemia reperfusion,
while Gclm+/- mice did not show any diﬀerence in similar parameters
with WT mice [29]. Yet, Gclm+/- mice, but not Gclm-/- mice, promoted
vascularization in hindlimb ischemia model [31]. There are number of
examples that suggest that redox signaling in response to ischemia
seems to be diﬀerent between heart and skeletal muscle. Myeloid-
speciﬁc catalase overexpression impaired limb vascularization [24],
while the same mice were protected from cardiac infarction [57].
Similarly, Glrx overexpression inhibited limb vascularization [48],
while it was protective in myocardial infarction in association with
NF-κB activation and inhibited apoptosis [58]. Cardiac tissue must be
more sensitive to ischemia as a vital organ compared to limb muscle. In
response to acute ischemia, post-ischemic cardiac function is mainly
determined by immediate cardiomyocyte apoptosis and mitochondrial
function, rather than neovascularization which takes a prolonged
amount of time. Whereas the functional outcome after hindlimb
ischemia is more directly aﬀected by revascularization potential. In
other words, cardiac cell survival is aﬀected by apoptotic signaling in
shorter time, while skeletal muscle cell survival is more reliant upon the
arteriogenesis and angiogenesis process. Therefore, oxidants-induced
angiogenesis signaling may be more critical to the ischemic limb
vascularization than cardiac infarction.
3. Molecular mechanism and protein targets
3.1. Redox signaling by thiol modiﬁcations
Animal studies reveal that a certain level of endogenous oxidants is
essential to promote VEGF signaling and ischemic limb vascularization.
Fluctuation of oxidants levels may control cellular signaling through
reversible post-translational modiﬁcation of protein thiols (-SH).
Reversible modiﬁcation on cysteine residues may alter protein function
including enzyme activity and protein-protein interaction [13,14,59].
Oxidants (ROS/RNS) react with thiolate anion (-S-) and form sulfenic
acid (-SOH) or S-nitrosothiol (-SNO). These relatively unstable inter-
mediates can react with abundant GSH in the cell, result in forming S-
glutathionylation or GSH protein adducts (R-SSG). Diﬀerential identi-
ﬁcation of S-nitrosylation (R-SNO) and S-glutathionylation (R-SSG) is
not easy since commonly used biotin-switch assay is not speciﬁc [60].
Nitrosative stress is shown to induce R-SSG in many proteins, suggest-
ing that R-SNO can be rapidly converted to R-SSG [61–63]. Alterna-
tively, oxidants activate GSH to GSH disulﬁde (GS-SG), S-nitrosoglu-
tathione (GSNO), or other reactive intermediate which react with
reduced thiol to form R-SSG [59]. GSH adducts are reversed to reduced
thiol in the process of “redox signaling” (Fig. 2). Glrx which catalyzes
removal of GSH adducts is a key to control redox signaling. In some
condition, Glrx also promotes protein-GSH adducts formation via
intermediate Glrx-SSG [64,65]. This raises the possibility that Glrx
may accelerate redox signaling by promoting dynamics of protein-GSH
adducts. Glutathione-S-transferases (GSTs) are potential enzymes which
catalyze GSH protein adducts formation. In particular GST-π is indi-
cated to promote GSH protein adducts in vitro [66] and in the lung [67].
In contrast, high levels of oxidants in pathological conditions can
further oxidize thiolate to sulﬁnic acid (-SO2H) and sulfonic acid
(-SO3H) which are irreversible modiﬁcations [68], leading to protein
Fig. 2. Redox signaling controlled by protein thiol modiﬁcations and glutaredoxin-1 (Glrx). Reactive oxygen and nitrogen species (ROS/RNS) react with thiolate anion (-S-) and form
sulfenic acid (-SOH) or S-nitrosylation (-SNO), which can further react with glutathione (GSH) to form S-glutathionylation (GSH adducts). Also, ROS/RNS react with GSH forming GSSG
or GSNO which may react with thiolate anion, and form reversible modiﬁcations. R-SSG formation can be catalyzed by glutathione-s-transferase (GST)-π. Glrx catalyzes reversing GSH
adducts to reduced thiol in mono-thiol exchange mechanism in the presence of GSH. Glrx may catalyze formation of GSH adducts in some conditions (dashed arrow). Catalase which
scavenges H2O2 can inhibit reversible thiol modiﬁcation including GSH adducts [108]. When oxidants levels increase too much, protein thiols can be irreversibly modiﬁed to sulﬁnic acid
(-SO2H) and sulfonic acid (-SO3H) which result in protein dysfunction or proteasomal degradation. Thioredoxin (Trx) mainly reduces intra- or inter-protein disulﬁde.
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dysfunction and proteasomal degradation (Fig. 2). Some proteins (e.g.
β-actin) are shown to be S-glutathionylated at basal level [69]. There-
fore, GSH adducts may be a mechanism to protect redox-sensitive
proteins from irreversible oxidation and degradation under ﬂuctuation
of oxidants levels. Further studies are required to conﬁrm this concept.
3.2. The targets for GSH adducts in vascularization
A large number of proteins with redox sensitive cysteine(s) have
been conﬁrmed to be modiﬁed with GSH adducts in vitro, but the
functional in vivo signiﬁcance has been demonstrated for limited
number of proteins [13]. Fewer targets still are known to be reversed
and functionally controlled by Glrx in vivo (Fig. 3).
3.2.1. VEGF receptor signaling
Downstream of VEGF receptor (VEGFR), protein tyrosine phospha-
tases (PTP) negatively regulate VEGF signaling [70] and their activity is
inhibited by oxidative modiﬁcation. PTP-1B inhibits phosphorylation of
VEGFR2 in endothelial cells [71], and oxidants inactivate PTP-1B via
GSH adducts on Cys215 [72]. Other phosphatases are also involved in
VEGFR2 signaling. Low molecular weight (LMW)-PTP (HCPTPA) was
found as an interacting protein with the kinase domain of VEGFR2 [73].
LMW-PTP regulates VEGF-induced phosphorylation of focal adhesion
kinase and its activity is inhibited by GSH adducts [74]. PTP1B-/- mice
demonstrated enhanced in vivo angiogenesis and cardiac function after
coronary artery ligation [75]. Moreover, EC-speciﬁc PTP1B-/- mice also
have potentiation of vascularization after femoral artery ligation [76].
Thus, inhibiting PTPs by GSH adducts may be one of targets which
oxidants promote during VEGF signaling and vascularization. Another
downstream target is calcium uptake by endoplasmic reticulum pump.
Sarcoplasmic-endoplasmic reticulum calcium ATPase 2b (SERCA2b) is
activated by GSH adducts on Cys674 [77]. Overexpression of Cys674Ser
mutant SERCA2 or Glrx inhibited VEGF-induced EC calcium inﬂux and
migration [47]. Furthermore, heterozygote mice which encode
Cys674Ser mutant SERCA2 showed impaired blood ﬂow recovery after
hindlimb ischemia and VEGF-induced angiogenic responses were
decreased in EC from the mouse [78,79]. Homozygotes of this knock-
in mouse impaired fetal development by lack of blood vessel formation,
indicating Cys674 of SERCA2 is required for successful fetal angiogen-
esis [78].
3.2.2. NF-κB signaling
Multiple components of the NF-κB pathway are inhibited by GSH
adducts. GSH adducts on inhibitor of nuclear factor kappa-B kinase
subunit β (IKKβ) [80], p50 [81], and p65 [48,65] subunits inactivate
transcriptional activity, therefore. Therefore, Glrx overexpression en-
hances NF-κB activation [48,82,83]. Glrx overexpressing TG mice
exhibit impaired vascularization with poor motor function recovery in
association with increased soluble VEGF receptor 1 (sVEGFR-1 also
known as sFlt-1) in muscles and plasma [48]. VEGF binds to VEGFR-1
(fms-like tyrosine kinase-1; Flt) with higher aﬃnity than VEGFR-2, but
VEGFR1 transduces a weaker signal than VEGFR-2, and a soluble splice
variant (sVEGFR-1) can capture VEGF ligand to prevent its binding to
VEGFR2 [84]. Upregulated Glrx induced the anti-angiogenic factor
sVEGFR-1 as well as Wnt5a, which may induce sVEGFR-1 expression
[85], in EC dependent on NF-κB expression [48]. Interestingly,
impaired hindlimb vascularization in diet-induced type 2 diabetic mice
was associated with increased sVEGFR-1 in the muscles [86], and Glrx
activity was upregulated in diabetic rat tissue [82]. Upregulated Glrx in
diabetes may be responsible for sVEGFR-1 induction and poor vascu-
larization. Since Glrx is a NF-κB dependent gene [87], activation of NF-
κB in diabetes [88,89] may induce Glrx. Subsequently Glrx-induced NF-
κB activation can generate deleterious inﬂammatory reaction [83].
Inhibition of NF-κB by mutant IκBα, which blocks its degradation and
works as a super repressor, increased disorganized vasculature and
decreased functional arteriogenesis in mouse ischemic muscle [90] and
enhanced tumor growth and neovascularization [91], suggesting that
ﬁne control of NF-κB activity is required to maintain normal vascular-
ization.
3.2.3. Hypoxia-inducible factor (HIF)-1α
HIF-1 is an essential transcriptional factor in response to hypoxia
and controls oxygen and nutrient delivery by promoting angiogenesis
and vascular remodeling. It is a heterodimeric factor that is composed
of an O2-regulated HIF-1α and a constitutively expressed HIF-1β
[92,93]. HIF-1α protein stability which is controlled by post-transla-
tional modiﬁcation critically determines HIF-1 activity. HIF-1α hydro-
xylation at proline 402 and 564 in the oxygen-dependent degradation
(ODD) domain by prolyl-hydroxylases (PHD) [94,95] is subjected to
ubiquitination by E3 ubiquitin ligase, von Hippel Lindau protein
(pVHL), and rapidly degraded by the proteasome. Under hypoxia,
PHD activity and subsequent HIF-1α hydroxylation are attenuated,
resulting in less degradation and accumulation of HIF-1α. In addition,
NO-mediated S-nitrosylation at Cys533 (mouse, human Cys520 equiva-
lent) in ODD domain of HIF-1α prevents degradation and enhances HIF-
1 activity [96]. Furthermore, this cysteine may form the more stable
GSH adduct. In fact, Glrx inhibition or increased GSH adducts in vitro
stabilized HIF-1α protein by preventing interaction with pVHL, and
mass spectrometry analysis recognized GSH adducts on Cys520 of HIF-
1α. Glrx-/- mice in vivo increased overall GSH adducts, HIF-1α, and
VEGF expression in ischemic muscles, and improved vascularization
after hindlimb ischemia [49]. Increased GSH adducts in ischemic
muscle may be a reﬂection of increased oxidants, but enhanced GSH
adducts by endogenous Glrx deletion paradoxically promote recovery
of ischemic limb via HIF-1α stabilization (Fig. 4). Previously reported
ROS-dependent HIF-1α activation [97] may be explained by this
mechanism of HIF-1α stabilization with GSH adducts.
3.2.4. Other targets of GSH adducts
Glrx overexpression is shown to protect EC barrier function via
activation of small Rho GTPase Rac1 which is inactivated by GSH
adducts under metabolic stress [98]. Decreased EC permeability by
enhanced barrier function may also contribute to inhibition of angio-
genesis by Glrx. There are other targets of GSH adducts which may not
Fig. 3. Glutaredoxin inhibits angiogenic pathway through multiple targets. NF-κB:
nuclear factor kappa B, sVEGFR1: soluble VEGF receptor 1 (or sFlt), HIF-1α: hypoxia-
inducible factor 1α, PTPs: protein tyrosine phosphatases, SERCA: sarcoplasmic-endoplas-
mic reticulum calcium ATPase. Arrows indicate activation. Red bars indicate inhibition.
Glrx may activates NF-κB, PTP1B or other PTPs, Rac1, while inhibits HIF-1α stability,
SERCA2 activity by removing GSH adducts. See the text in details. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of
this article).
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promote vascularization. For instance, eNOS is known to be uncoupled
by GSH adducts on critical cysteine residues [99]. Lower NO production
by eNOS dysfunction is expected to inhibit angiogenesis, but increased
superoxide anion or peroxynitrite may activate other angiogenic path-
ways. Glrx may target many proteins with GSH adducts, but in vivo Glrx
contributes to the anti-angiogenic pathway as shown in Glrx-/- mice.
Further mechanisms in which Glrx activates a certain signaling cascade
in speciﬁc pathological model should be explored.
4. Summary and translational implication
In summary, studies using genetically modiﬁed mice indicate
endogenous oxidants are essential to promote ischemic limb vascular-
ization, which suggests caution should be taken for the therapeutic use
of antioxidants since excess antioxidants may not only be ineﬀective
but can be detrimental in the ischemic limb. There are several targets
which oxidants activate angiogenic pathways by forming reversible
thiol modiﬁcation with GSH adducts such as HIF-1α⊡ Therefore,
enhanced GSH adducts by inhibiting Glrx can promote ischemic limb
vascularization.
Hind limb ischemia is used as a model for human peripheral artery
disease (PAD). Clinical symptom of PAD is from acute reversible
hypoperfusion which may cause intermittent claudication to critical
limb ischemia which is chronic artery occlusion causing tissue necrosis
[100]. Risk factors of PAD are age, smoking, and diabetes, and its
pathogenesis is associated with atherosclerosis, endothelial dysfunc-
tion, and inﬂammation. Impaired angiogenesis and reduced microcir-
culation in the muscle of PAD patients potentiate limb ischemia [101].
Of interest critical limb ischemia patients have higher levels of plasma
VEGF-A [102], indicating that VEGF downstream signaling may be
aﬀected in these patients. This may be incompatible with hindlimb
ischemia of atherosclerotic animals which still respond exogenous
VEGF [37,38]. Supervised exercise is recommended as eﬀective therapy
for PAD patients among other medical interventions [103,104]. This is
supported by a mouse study which showed that exercise improved
vascularization after femoral artery ligation dependent on inducible
nitric oxide synthase (iNOS) in myeloid cells [105]. Oxidants derived
from iNOS may promote vascularization and stimulate even tumor
angiogenesis because high expression of iNOS relates to human cancer
progression [106]. It should be noted, however, that PAD patients
usually have a background of atherosclerosis or diabetes which may be
associated with higher levels of oxidants and inﬂammation. These
clinical conditions are not necessarily comparable with healthy young
mice. Furthermore, stimulating angiogenesis may exacerbate athero-
sclerosis [107], suggesting complexity of treatment to PAD. High fat
diet-fed mice [86] or hypercholesterolemic animals [37,38] show
impaired vascularization after hindlimb ischemia. Future studies in
such pathological models will be more translational to ﬁnd therapeutic
targets.
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